Skip to main content
. 2019 Oct 5;20(19):4931. doi: 10.3390/ijms20194931

Figure 1.

Figure 1

Schematic representation of principal interactions targeted by immune checkpoints inhibitors, including PD-1 (programmed cell death protein) and PD-L1 (programmed cell death ligand 1 protein), CTLA4 (cytotoxic T-lymphocyte antigen 4), B7-1, TCR and MHC (major histocompatibility complex) (with the co-function of CD3 and CD8 molecules) pathways, between T-lymphocytes (T cells) and antigen presenting cells (APCs).